Rapid Micro Biosystems(US:RPID) Globenewswire·2026-01-13 21:15Core Insights - The company reported preliminary unaudited revenue for Q4 and full year 2025, indicating strong growth in both periods [1][4]. Q4 2025 Performance - Q4 2025 revenue is expected to be approximately $11.3 million, reflecting a growth of about 37% compared to the same period last year [2][8]. - Recurring revenue for Q4 2025 is anticipated to be around $4.6 million, showing a growth of approximately 10% year-over-year [2]. - The company achieved a record placement of 16 new Growth Direct systems and completed the validation of three customer systems in Q4 [2]. Full Year 2025 Performance - Total revenue for the full year 2025 is projected to be approximately $33.6 million, representing a growth of about 20% compared to the previous year [3][8]. - Recurring revenue for the full year is expected to be around $17.8 million, indicating a growth of approximately 15% year-over-year [3]. - The company placed a total of 28 new Growth Direct systems and validated 18 customer systems throughout 2025, bringing the cumulative total to 190 systems placed globally with 155 validated [3]. Management Commentary - The President and CEO expressed satisfaction with the record results for Q4, which exceeded the raised guidance from November [4]. - The company is positioned for continued growth in 2026, supported by a strong execution track record and advancements in its strategic partnership with MilliporeSigma [4]. Upcoming Events - The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, with a live webcast available for investors [6].